Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/169339NOVEL NUCLEIC ACID MOLECULE
WO 11.08.2022
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Appl.No PCT/KR2022/001874 Applicant ST PHARM CO., LTD. Inventor KIM, Kyungjin
The present invention relates to a nucleic acid molecule, including a nucleic acid encoding a signal peptide and a nucleic acid encoding an antigen, for prevention or treatment of viral infection or cancer. In addition, the present invention relates to a vaccine composition containing the nucleic acid molecule for prevention or treatment of viral infection or cancer. The nucleic acid molecule according to the present invention is superb in terms of intracellular protein expression rate and extracellular protein secretion. In addition, when administered in vivo, the nucleic acid molecule allows the subject to acquire the humoral immunity of inducing antigen-specific neutralizing antibodies and the cellular immunity of increasing an amount of immune cells directly involved in killing viruses and as such, can be advantageously utilized as a vaccine for prevention and treatment of virus infection or cancer.
2.WO/2022/170119ADJUVANTED MUCOSAL SUBUNIT VACCINES FOR PREVENTING SARS-COV-2 TRANSMISSION AND INFECTION
WO 11.08.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/015349 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor BERZOFSKY, Jay A.
Immunogenic compositions that include SARS-CoV-2 spike (S) protein, S1 protein, or S2 protein, and an adjuvant, such as alum, or a combination of CpG oligodeoxynucleotide, Poly I:C, and IL-15, and nanoparticle compositions that include SARS-CoV-2 S protein, S1 protein, or S2 protein, and CpG oligonucleotide, poly(I:C), and IL-15, are provided. Also provided are methods of using such compositions, for example a prime intramuscular administration followed by one or more intranasal boosters that include the disclosed nanoparticles, to generate an immune response to SARS-CoV-2 in a subject, for example respiratory mucosal immunity, for example to prevent SARS-CoV-2 infection or transmission to other subjects.
3.WO/2022/165980MANGANESE NANO-ADJUVANT, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 11.08.2022
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No PCT/CN2021/085578 Applicant THE GBA NATIONAL INSTITUTE FOR NANOTECHNOLOGY INNOVATION Inventor CHEN, Chunying
A manganese nano-adjuvant, a preparation method therefor and a use thereof in the preparation of vaccines. The manganese nano-adjuvant comprises trimanganese tetroxide nano-particles and template molecules wrapped around the trimanganese tetroxide nano-particles. The molar ratio of the template molecules to manganese elements is 1:(10-1000). Each template molecule comprises a template protein and fragments or polypeptides thereof, and the template protein is selected from one or more of bovine serum albumin, human serum albumin, murine serum albumin, transferrin, and antigen protein. The average particle size of the manganese nano-adjuvant is 1-100 nm. The manganese nano-adjuvant can effectively deliver immune antigens to lymph node tissues, enhance cell internalization of the immune antigens, and efficiently activate immune cells.
4.20220249655AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LYOPHILIZED FORM (VARIANTS)
US 11.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17715945 Applicant Federal State Budgetary Institution "National Research Centre for Epidemiology And Microbilogy Named Inventor Olga Vadimovna Zubkova

The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in lyophilized (freeze-dried) form, which contains a single active component, comprising the expression vector including either the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, and an integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the genome of the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, and an integrated expression cassette is selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The genome of the recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.

A buffer solution for reconstitution of the lyophilized form of the agent may contain the following, mass %: tris from 0.0180-0.0338; sodium chloride from 0.1044-0.1957; sucrose from 5.4688-10.2539; magnesium chloride hexahydrate from 0.0015-0.0028; EDTA from 0.0003-0.0005; polysorbate-80 from 0.0037-0.0070; and water to fill.

The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.

5.WO/2022/167666SARBECOVIRUS BINDERS
WO 11.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2022/052919 Applicant VIB VZW Inventor SAELENS, Xavier
The invention relates to agents binding to sarbecoviruses of multiple clades and potently neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Application and uses of these agents are further part of this invention.
6.11406702Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine
US 09.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17228699 Applicant David Gordon Bermudes Inventor David Gordon Bermudes

A live genetically engineered bacterium, comprising a genetically engineered construct comprising a nucleic acid sequence encoding at least one portion of a SARS-CoV-2 antigen, the live genetically engineered bacterium being adapted for administration to a human or animal and colonization of at least one tissue under non-lethal conditions. The antigen is preferably the SARS-CoV-2 spike protein. The nucleic acid sequence preferably includes an associated promoter.

7.20220241400IMMUNOMODULATION PLATFORM AND METHODS OF USE
US 04.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17589427 Applicant PROVAXUS, INC. Inventor Viktor Stolc

Disclosed herein are methods, systems, and compositions comprising genetically modified probiotic microorganisms. In some embodiments, the genetically modified probiotic microorganisms produce at least one viral coat protein and/or at least one fusion protein comprising an antigenic polypeptide linked to a viral coat protein.

8.WO/2022/164823INHIBITION OF DEGRANULATION OF NEUTROPHIL CELLS IN COVID-19 PATIENTS
WO 04.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/013744 Applicant UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. Inventor MCLEISH, Kenneth R.
In certain aspects, provided herein are methods of inhibiting neutrophil degranulation in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by administering a composition comprising (a) a TAT-fusion protein comprising an 11 amino acid cell penetrating peptide TAT operably linked to an N-terminal SNARE domain of SNAP-23 (TAT-SNAP-23), and/or a TAT-fusion protein comprising an 11 amino acid cell penetrating peptide TAT operably linked to a SNARE domain of syntaxin-4 (TAT-STX-4), wherein the inhibition is compared to a control.
9.WO/2022/163902VACCINE COMPOSITION FOR PREVENTING HUMAN INFECTIOUS SARS CORONAVIRUS AND ALLEVIATING INFECTION SYMPTOMS
WO 04.08.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/KR2021/003046 Applicant LIBENTECH CO.,LTD. Inventor JANG, Hyun
The present invention relates to a vaccine composition for preventing human infectious SARS coronavirus (SARS-CoV-2, COVID-19) and alleviating infection symptoms. The vaccine composition, of the present invention, comprising a recombinant Newcastle disease virus, which expresses a SARS-CoV-2 RBD protein on the surface thereof, or an antigen purified therefrom induces immune responses that can fight COVID-19 infection, and thus can be effectively used as a vaccine for preventing and treating SARS-CoV-2 infection.
10.WO/2022/161495RECOMBINANT SARS-COV-2 VACCINE
WO 04.08.2022
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2022/075134 Applicant GENESAIL BIOTECH (SHANGHAI) CO., LTD. Inventor LIANG, Min
Provided are SARS-CoV-2 vaccines useful for treating or protecting a subject from infection by SARS-CoV-2. The SARS-CoV-2 vaccines contain nucleic acids encoding at least one type of S protein variant, and other factors useful for treating or protecting a subject from infection by SARS-CoV-2, or expression vectors or viruses containing such nucleic acids, or host cells containing such nucleic acids or expression vectors.